HK1202459A1 - Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders - Google Patents

Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders Download PDF

Info

Publication number
HK1202459A1
HK1202459A1 HK15103243.2A HK15103243A HK1202459A1 HK 1202459 A1 HK1202459 A1 HK 1202459A1 HK 15103243 A HK15103243 A HK 15103243A HK 1202459 A1 HK1202459 A1 HK 1202459A1
Authority
HK
Hong Kong
Prior art keywords
patient
sleep
pharmaceutically acceptable
treatment
antagonist
Prior art date
Application number
HK15103243.2A
Other languages
English (en)
Chinese (zh)
Inventor
．丹尼
W.S.丹尼
．傑克遜
M.杰克逊
．索南伯格
G．索南伯格
Original Assignee
辉瑞大药厂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 辉瑞大药厂 filed Critical 辉瑞大药厂
Publication of HK1202459A1 publication Critical patent/HK1202459A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15103243.2A 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders HK1202459A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261655177P 2012-06-04 2012-06-04
US61/655,177 2012-06-04
US201361812416P 2013-04-16 2013-04-16
US61/812,416 2013-04-16
PCT/IB2013/054177 WO2013182933A1 (en) 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Publications (1)

Publication Number Publication Date
HK1202459A1 true HK1202459A1 (en) 2015-10-02

Family

ID=48700662

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103243.2A HK1202459A1 (en) 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Country Status (16)

Country Link
US (1) US9370516B2 (https=)
EP (1) EP2854856B1 (https=)
JP (1) JP6165852B2 (https=)
KR (1) KR101708989B1 (https=)
CN (1) CN104334193A (https=)
AU (1) AU2013273263B2 (https=)
BR (1) BR112014029577A2 (https=)
CA (1) CA2874196C (https=)
ES (1) ES2716303T3 (https=)
HK (1) HK1202459A1 (https=)
IL (1) IL235883A0 (https=)
MX (1) MX2014014813A (https=)
RU (1) RU2600895C2 (https=)
SG (1) SG11201407387UA (https=)
WO (1) WO2013182933A1 (https=)
ZA (1) ZA201408672B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175272A (zh) * 2015-08-31 2015-12-23 吴玲 制备r-5-溴-1-氨基茚满的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP4717444B2 (ja) * 2002-12-20 2011-07-06 ザ マクレーン ホスピタル コーポレーション 睡眠／覚醒サイクルの正規化のための化合物
US20050171132A1 (en) * 2003-09-26 2005-08-04 Zhili Xin Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
US20090149512A1 (en) * 2004-05-14 2009-06-11 Novo Nordisk A/S Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases
US20090253673A1 (en) * 2006-07-12 2009-10-08 Min Ge Substituted Pyrazoles as Ghrelin Receptor Antagonists
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
DK2547679T3 (en) 2010-03-19 2016-01-11 Pfizer 2,3 dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of ghrelin receptor

Also Published As

Publication number Publication date
CN104334193A (zh) 2015-02-04
KR20150013236A (ko) 2015-02-04
EP2854856A1 (en) 2015-04-08
BR112014029577A2 (pt) 2017-06-27
AU2013273263A1 (en) 2014-11-27
KR101708989B1 (ko) 2017-02-21
ZA201408672B (en) 2016-09-28
WO2013182933A1 (en) 2013-12-12
MX2014014813A (es) 2015-02-12
CA2874196C (en) 2016-12-06
ES2716303T3 (es) 2019-06-11
US20150119381A1 (en) 2015-04-30
JP6165852B2 (ja) 2017-07-19
RU2014146109A (ru) 2016-07-27
IL235883A0 (en) 2015-01-29
EP2854856B1 (en) 2019-01-23
JP2015518876A (ja) 2015-07-06
US9370516B2 (en) 2016-06-21
AU2013273263B2 (en) 2017-08-24
RU2600895C2 (ru) 2016-10-27
SG11201407387UA (en) 2014-12-30
CA2874196A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
JP5076159B2 (ja) アセチルコエンザイムａカルボキシラーゼ（ａｃｃ）阻害薬としてのスピロクロマノン誘導体
CN103874695B (zh) 2‑吡啶基氧基‑4‑腈食欲素受体拮抗剂
ES2397188T3 (es) Compuestos de diazepano sustituidos como antagonistas del receptor de orexina
JP5319550B2 (ja) 置換スピロクロマノン誘導体
JP4881476B2 (ja) ピリジルピペリジン・オレキシン受容体アンタゴニスト
JP5271917B2 (ja) スピロクロマノン誘導体
US9586934B2 (en) 2-pyridyloxy-4-methyl orexin receptor antagonists
JP5501256B2 (ja) 新規スピロクロマノンカルボン酸
US10227336B2 (en) Pyrazole orexin receptor antagonists
JP2009516742A (ja) インドールオレキシン受容体アンタゴニスト
JP2011530522A (ja) トリピリジルカルボキサミドオレキシン受容体拮抗薬
US20150322039A1 (en) 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
JP2012507539A (ja) ２，５−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
JP2012507540A (ja) ピリダジンカルボキサミド・オレキシン受容体アンタゴニスト
US20170320865A1 (en) Oxazole orexin receptor antagonists
EP3083642B1 (en) Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
WO2006076796A1 (en) Cathepsin k inhibitors and obesity
HK1202459A1 (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
CN101155792A (zh) 氨基丙氧基苯基增食欲素受体拮抗剂
JP6327515B2 (ja) ナルコレプシーまたは摂食障害の治療剤